<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510157</url>
  </required_header>
  <id_info>
    <org_study_id>711/19-3-15</org_study_id>
    <nct_id>NCT02510157</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone on the Action of Sugammadex</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the possible clinical effect of dexamethasone on the action of
      sugammadex when it is administered to reverse deep neuromuscular blockade caused by
      rocuronium in laparoscopic cholecystectomies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to train-of-four (TOF) ratio of 0.9 since administration of sugammadex</measure>
    <time_frame>minutes after administration of sugammadex (0 to 30 minutes)</time_frame>
    <description>measurement of time after administration of the reversal agent (sugammadex) to achieve train-of-four (TOF0 ratio of 0.9 (up to 30 minutes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>1, 6, 12, 24 hours postoperatively</time_frame>
    <description>Assessed by Numeric Rating Scale 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>1, 6, 12, 24 hours postoperatively</time_frame>
    <description>Assessed by nausea/vomiting scale (11. Myles PS, Wengritzky R. Simplified postoperative nausea and vomiting impact scale for audit and post-discharge review. Br J Anaesth 2012; 108: 423-429)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time from end of surgery to extubation of patient</measure>
    <time_frame>minutes after administration of sugammadex (0 to 30 minutes)</time_frame>
    <description>measurement of time after administration of the reversal agent (sugammadex) to achieve extubation of patient (up to 30 minutes)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>active comparator</description>
    <arm_group_label>dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>placebo controlled intervention</description>
    <arm_group_label>normal saline</arm_group_label>
    <other_name>N/S 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery</description>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 18-70 years

          -  laparoscopic cholecystectomy

          -  operation &lt; 3 hours

        Exclusion Criteria:

          -  age &lt;18 or &gt;70 years old

          -  ASA physical status &gt;3

          -  central nervous system diseases

          -  severe psychiatric disorders under treatment

          -  cognitive dysfunction

          -  known or suspected allergy to the administered drugs

          -  operations &gt; 3 hours

          -  surgical intraoperative complications-open cholecystectomy

          -  severe renal or liver disease

          -  diabetes melitus

          -  immunosuppressed patients

          -  chronic immunosuppresant therapy (corticosteroids or other drugs)

          -  all contraindications to corticosteroids administration

          -  patiens on chronic use of opioids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2nd Department of Anesthesiology, Attikon Hospital, 1 Rimini str.</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>October 2, 2016</last_update_submitted>
  <last_update_submitted_qc>October 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Chrysanthi Batistaki</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology, 2nd Department of Anesthesiology, School of Medicine, University of Athens, Greece</investigator_title>
  </responsible_party>
  <keyword>sugammadex</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>neuromuscular blockade</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

